Medical spas built semaglutide and tirzepatide programs faster than most medical, nursing and pharmacy boards wrote rules for them, and the gap is closing from two directions at once. An FDA warning letter to a Texas compounding pharmacy on September 18, 2026 shows how closely the agency is scrutinizing where a med spa's product comes from. State boards are watching the clinical side just as closely: who performs the exam, who writes the prescription, and whether the staff member giving the injection was ever lawfully delegated to do so.
Supervision And The Medical Director Requirement
Florida requires every clinic, including many med spas, to appoint a medical director who accepts written legal responsibility for the clinic's services, while Arizona lets a nurse practitioner with full practice authority carry that same responsibility without a supervising physician. A med spa should confirm which model its state follows before assuming either one automatically extends to a GLP-1 program layered onto injectables. That responsibility is not satisfied by a name on a wall certificate. Texas requires the delegating physician to review charts and meet periodically face to face with the nurse practitioner or physician assistant under a written prescriptive authority agreement, and whether that agreement already extends to a GLP-1 program is a question to check rather than assume. A med spa that assumes one medical director agreement covers every service line inherits the first gap a board investigator finds.
The Good Faith Exam Before Any GLP-1 Prescription
A good faith exam is the individualized clinical evaluation required before a prescriber orders semaglutide, tirzepatide, or any other drug in the GLP-1 class, and it is not the same thing as an intake questionnaire. Which categories of clinician may perform the exam, whether telehealth can satisfy it, and whether it must include a synchronous visit are questions state boards answer differently, and a med spa seeing patients from more than one state cannot assume its home state's answer travels. Dosing and syringe-instruction errors compound that exposure once a program is running without a documented exam, a pattern addressed separately in Compounded GLP-1 Dosing Errors and Syringe Instructions.
Delegation Agreements For Nurse Practitioners And Physician Assistants
Delegation is the legal mechanism that lets a nurse practitioner or physician assistant prescribe a GLP-1 drug at a med spa without a physician's signature on every chart. Texas is one state where the rule is explicit: the Texas Board of Nursing requires a physician's delegation of prescriptive authority before an advanced practice registered nurse can prescribe or provide the medical aspects of care. Other states set different thresholds for chart review, on-site presence, or which drug classes a delegation agreement can cover. A delegation agreement drafted for injectables does not automatically extend to a GLP-1 program, and a med spa that never checked is operating that program without the authority it assumes it has.
Sourcing Compounded GLP-1 Drugs The Program Can Defend
A med spa's GLP-1 program is only as defensible as the pharmacy behind it. The FDA's September 18, 2026 warning letter to a Texas compounding pharmacy found its tirzepatide and semaglutide combination products were essentially copies of FDA-approved drugs rather than individualized compounds, a finding tied to the volume the pharmacy was producing. Enforcement discretion for compounding copies of approved tirzepatide and semaglutide products ended on March 5, 2025, and April 24, 2025, respectively. A med spa that cannot show its supplier operates under the 503A/503B framework, follows cGMP, and tracks the beyond-use date on every unit it dispenses has no answer when a board or the FDA asks where the product came from, or whether that supplier also meets USP 797/800 sterile compounding standards. Manufacturer-driven litigation over these same products is covered separately in Brand Manufacturer Lawsuits Over Compounded GLP-1 Drugs and is not the subject of this article. How a program may advertise those drugs is a separate question, covered in Compounded GLP-1 Marketing After the Shortage Ended.
Supervision, delegation and the good faith exam are three separate legal requirements, not one compliance checkbox, and a GLP-1 program is only as defensible as the weakest of the three.
Why Early Legal Counsel Is Critical
It is critical that med spas and their supervising physicians promptly retain experienced healthcare defense counsel once a board inquiry, a supplier's FDA warning letter, or a payer audit touches a GLP-1 program. Early legal intervention can protect the practice's licenses, ensure board and agency communications are handled correctly, avoid inadvertent admissions about supervision or delegation gaps, and preserve defenses before documentation is created or altered under pressure. Delaying counsel until after a board complaint is filed can significantly affect the outcome and expose the practice and its supervising clinicians to discipline that earlier engagement could have prevented.
How Health Law Alliance Can Help
Health Law Alliance represents med spas, physician practices and wellness clinics in delegation, scope-of-practice and sourcing matters involving GLP-1 programs nationwide. Health Law Alliance's attorneys have overseen 2,000+ audits and handled 5,000+ matters, with 25+ years of experience. If your GLP-1 program is under board inquiry or you want its supervision and sourcing arrangements reviewed before a regulator does, contact our compounding pharmacy defense attorneys for a free, confidential consultation.
